内容紹介
アミロイドPETは、アルツハイマー病における老人斑密度を推定し、最早期の病態を検出できる診断法としての意義が確立された。タウPETは神経障害の最も客観的な指標として期待されるが、現在実証研究が進められているところである。これらの病態特異的画像診断は、認知症診療においても早期の正確な診断をもたらすと期待される。
Clinical application and diagnostic significance of emerging techniques of amyloid and tau PET imaging will be discussed in this article. Amyloid imaging has been established as a reliable imaging biomarker which enable us to visualize the deposition of fibrillary amyloid ß (senile plaque) in the living human brain. In the past decade, this technique significantly accelerated clinical research for early diagnosis and development of disease modifying drugs for Alzheimer’s disease (AD). Tau imaging is expected to be a useful imaging biomarker to visualize neurofibrillary tangles which plays an important role not only in AD but also non-Alzheimer tauopathies, however, still need to be confirmed by histopathological examinations.
目次
Clinical application and diagnostic significance of emerging techniques of amyloid and tau PET imaging will be discussed in this article. Amyloid imaging has been established as a reliable imaging biomarker which enable us to visualize the deposition of fibrillary amyloid ß (senile plaque) in the living human brain. In the past decade, this technique significantly accelerated clinical research for early diagnosis and development of disease modifying drugs for Alzheimer’s disease (AD). Tau imaging is expected to be a useful imaging biomarker to visualize neurofibrillary tangles which plays an important role not only in AD but also non-Alzheimer tauopathies, however, still need to be confirmed by histopathological examinations.